Compare KTOS & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTOS | ICLR |
|---|---|---|
| Founded | 1994 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 9.3B |
| IPO Year | 1999 | 2001 |
| Metric | KTOS | ICLR |
|---|---|---|
| Price | $57.17 | $172.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 13 |
| Target Price | $96.71 | ★ $178.62 |
| AVG Volume (30 Days) | ★ 3.8M | 805.3K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $751,900,000.00 | N/A |
| Revenue This Year | $26.15 | N/A |
| Revenue Next Year | $23.43 | N/A |
| P/E Ratio | $623.40 | ★ $12.91 |
| Revenue Growth | ★ 12.44 | N/A |
| 52 Week Low | $43.09 | $66.57 |
| 52 Week High | $134.00 | $203.91 |
| Indicator | KTOS | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 57.57 |
| Support Level | $52.49 | $172.65 |
| Resistance Level | $58.88 | $188.49 |
| Average True Range (ATR) | 3.78 | 6.78 |
| MACD | -0.16 | 0.57 |
| Stochastic Oscillator | 43.56 | 73.21 |
Kratos Defense & Security Solutions Inc develops and fields transformative, affordable technology, platforms, and systems. The company has two segments; The Kratos Government Solutions (KGS) segment is comprised of an aggregation of KGS operating segments, including its microwave electronic products, space, training, and cybersecurity, C5ISR/modular systems, turbine technologies, and defense and rocket support services operating segments and The Unmanned Systems segment consists of unmanned aerial, unmanned ground, unmanned seaborne and related command, control, and communications system businesses. The company derives a majority of its revenue from the Kratos Government Solutions segment.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.